CNRS, UMR Ecofog, Université des Antilles et de la Guyane, Cayenne, France.
J Ethnopharmacol. 2009 Oct 29;126(1):114-8. doi: 10.1016/j.jep.2009.07.037. Epub 2009 Aug 7.
Our objective was to assess whether it could be contemplated to recommend Quassia amara young leaf tea for treatment against malaria, and if yes, set up a standard protocol for preparing the herbal tea.
The leaf tea was extracted with methylene chloride and the organic extract was fractionated with HPLC. Pure compounds were characterized and their in vitro cytotoxicity and antiplasmodial activity was determined.
We discovered that antimalarial Quassia amara young leaf tea contains several quassinoids: simalikalactone D (SkD, 1), picrasin B (2), picrasin H (3), neoquassin (4), quassin (5), picrasin I (6) and picrasin J (7). These last two compounds are new. In addition, our experiments demonstrate that both biological activity and cytotoxicity of the remedy may be attributed solely to the presence of SkD.
In conclusion, this preparation should not be recommended for treatment of malaria until a clinical study in humans is performed with SkD.
本研究旨在评估是否可以考虑推荐苦木嫩叶茶用于疟疾治疗,如果可以,制定一个草药茶的标准制备方案。
用二氯甲烷提取叶茶,用 HPLC 对有机提取物进行分级。对纯化合物进行了表征,并测定了其体外细胞毒性和抗疟原虫活性。
我们发现,抗疟苦木嫩叶茶含有几种苦木素:西玛利考酮 D(SkD,1)、比卡林 B(2)、比卡林 H(3)、新苦木(4)、苦木(5)、比卡林 I(6)和比卡林 J(7)。后两种化合物为新化合物。此外,我们的实验表明,该药物的生物活性和细胞毒性可能仅归因于 SkD 的存在。
总之,在对 SkD 进行人体临床试验之前,不应推荐该制剂用于疟疾治疗。